Erythropoietin: a candidate compound for neuroprotection in schizophrenia
Hannelore Ehrenreich(Max Planck Institute of Experimental Medicine), Anna‐Leena Sirén(University of Würzburg), Friederike Knerlich‐Lukoschus(Max Planck Society), Martin Hasselblatt(University Hospital Münster), Anthony Cerami(Araim Pharmaceuticals (United States)), Michael Brines(Northwell Health), Sonja Jacob(Max Planck Society), Helge Woldt(Max Planck Institute for Dynamics and Self-Organization), Peter Falkai(Ludwig-Maximilians-Universität München), Martin Béhé(Paul Scherrer Institute), Wolfgang Becker(University of Göttingen), W. Maier(University of Bonn), N. von Ahsen(University of Göttingen), E. Rüther(Max Planck Institute for Dynamics and Self-Organization), Wolfgang Brück(Universitätsmedizin Göttingen), J. Meller(University of Göttingen), Detlef Degner(Max Planck Institute for Dynamics and Self-Organization)
Cited by 208
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Mind Reading: Neural Mechanisms of Theory of Mind and Self-Perspective
|NeuroImage|2001|1k